
    
      A single-centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4
      groups of 18 healthy subjects each. This study consisted of a once-daily administration of
      BIA 9 1067 (5 mg, 15 mg or 50 mg) or placebo for 18 days. Twelve (12) hours after the BIA 9
      1067 dose, a single-dose of levodopa/carbidopa 100/25 mg was administered on Day 11 and a
      single-dose of levodopa/benserazide 100/25 mg was administered on Day 18.
    
  